A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Latest Information Update: 24 Feb 2025
At a glance
- Drugs Ibrutinib (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms iFCR
Most Recent Events
- 18 Feb 2025 Planned End Date changed from 1 Jan 2026 to 1 Jan 2027.
- 05 Jan 2024 Planned End Date changed from 1 Jan 2025 to 1 Jan 2026.
- 13 Sep 2023 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2025.